Trump's Controversial Health Agency Picks Stir Debate
Martin Makary, President-elect Trump's nominee for FDA commissioner, is an executive at Sesame, a telehealth company involved in prescribing compounded weight-loss drugs. His confirmation could influence FDA policies affecting the compounding of cheaper drug versions amid ongoing disputes between branded drug manufacturers and compounding pharmacies. The FDA's role in determining drug shortages, which allows pharmacies to compound drugs, is central to this issue.